Advertisement
Loading...

cbdMD, Inc.

YCBDAMEX
Healthcare
Drug Manufacturers - Specialty & Generic
$0.77
$-0.04(-5.32%)
U.S. Market opens in 28h 22m

cbdMD, Inc. Fundamental Analysis

cbdMD, Inc. (YCBD) shows weak financial fundamentals with a PE ratio of -0.01, profit margin of -15.54%, and ROE of -37.76%. The company generates $5.7B in annual revenue with weak year-over-year growth of -1.50%.

Key Strengths

Cash Position33736.34%
PEG Ratio-0.00
Current Ratio2.82

Areas of Concern

ROE-37.76%
Operating Margin-14.20%
We analyze YCBD's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -266.3/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-266.3/100

We analyze YCBD's fundamental strength across five key dimensions:

Efficiency Score

Weak

YCBD struggles to generate sufficient returns from assets.

ROA > 10%
-7.17%

Valuation Score

Excellent

YCBD trades at attractive valuation levels.

PE < 25
-0.01
PEG Ratio < 2
-0.00

Growth Score

Moderate

YCBD shows steady but slowing expansion.

Revenue Growth > 5%
-1.50%
EPS Growth > 10%
39.11%

Financial Health Score

Excellent

YCBD maintains a strong and stable balance sheet.

Debt/Equity < 1
0.04
Current Ratio > 1
2.82

Profitability Score

Weak

YCBD struggles to sustain strong margins.

ROE > 15%
-3776.22%
Net Margin ≥ 15%
-15.54%
Positive Free Cash Flow
No

Key Financial Metrics

Is YCBD Expensive or Cheap?

P/E Ratio

YCBD trades at -0.01 times earnings. This suggests potential undervaluation.

-0.01

PEG Ratio

When adjusting for growth, YCBD's PEG of -0.00 indicates potential undervaluation.

-0.00

Price to Book

The market values cbdMD, Inc. at 0.00 times its book value. This may indicate undervaluation.

0.00

EV/EBITDA

Enterprise value stands at -2.79 times EBITDA. This is generally considered low.

-2.79

How Well Does YCBD Make Money?

Net Profit Margin

For every $100 in sales, cbdMD, Inc. keeps $-15.54 as profit after all expenses.

-15.54%

Operating Margin

Core operations generate -14.20 in profit for every $100 in revenue, before interest and taxes.

-14.20%

ROE

Management delivers $-37.76 in profit for every $100 of shareholder equity.

-37.76%

ROA

cbdMD, Inc. generates $-7.17 in profit for every $100 in assets, demonstrating efficient asset deployment.

-7.17%

Following the Money - Real Cash Generation

Operating Cash Flow

cbdMD, Inc. generates limited operating cash flow of $-1.54B, signaling weaker underlying cash strength.

$-1.54B

Free Cash Flow

cbdMD, Inc. generates weak or negative free cash flow of $-1.71B, restricting financial flexibility.

$-1.71B

FCF Per Share

Each share generates $-163.32 in free cash annually.

$-163.32

FCF Yield

YCBD converts -218.37% of its market value into free cash.

-218.37%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.01

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.00

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.001

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.001

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.04

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.82

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.38

vs 25 benchmark

ROA

Return on assets percentage

-0.07

vs 25 benchmark

ROCE

Return on capital employed

-0.09

vs 25 benchmark

How YCBD Stacks Against Its Sector Peers

MetricYCBD ValueSector AveragePerformance
P/E Ratio-0.0128.62 Better (Cheaper)
ROE-37.76%783.00% Weak
Net Margin-15.54%-48181.00% (disorted) Weak
Debt/Equity0.040.39 Strong (Low Leverage)
Current Ratio2.824.12 Strong Liquidity
ROA-7.17%-21914.00% (disorted) Weak

YCBD outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews cbdMD, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-88.83%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-103.95%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

96.68%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ